CN109535245A - 长效凝血因子和生产它们的方法 - Google Patents

长效凝血因子和生产它们的方法 Download PDF

Info

Publication number
CN109535245A
CN109535245A CN201811365443.5A CN201811365443A CN109535245A CN 109535245 A CN109535245 A CN 109535245A CN 201811365443 A CN201811365443 A CN 201811365443A CN 109535245 A CN109535245 A CN 109535245A
Authority
CN
China
Prior art keywords
ctp
another embodiment
coagulation factor
polypeptide
fix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811365443.5A
Other languages
English (en)
Chinese (zh)
Inventor
U·E·菲马
G·哈特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opko Biologics Ltd
Original Assignee
Opko Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48983616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN109535245(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/372,540 external-priority patent/US8759292B2/en
Application filed by Opko Biologics Ltd filed Critical Opko Biologics Ltd
Publication of CN109535245A publication Critical patent/CN109535245A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Glass Compositions (AREA)
CN201811365443.5A 2012-02-14 2013-02-05 长效凝血因子和生产它们的方法 Pending CN109535245A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/372,540 2012-02-14
US13/372,540 US8759292B2 (en) 2006-02-03 2012-02-14 Long-acting coagulation factors and methods of producing same
CN201380019660.8A CN104427994A (zh) 2012-02-14 2013-02-05 长效凝血因子和生产它们的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380019660.8A Division CN104427994A (zh) 2012-02-14 2013-02-05 长效凝血因子和生产它们的方法

Publications (1)

Publication Number Publication Date
CN109535245A true CN109535245A (zh) 2019-03-29

Family

ID=48983616

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811365443.5A Pending CN109535245A (zh) 2012-02-14 2013-02-05 长效凝血因子和生产它们的方法
CN201380019660.8A Pending CN104427994A (zh) 2012-02-14 2013-02-05 长效凝血因子和生产它们的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380019660.8A Pending CN104427994A (zh) 2012-02-14 2013-02-05 长效凝血因子和生产它们的方法

Country Status (22)

Country Link
EP (4) EP3326642B1 (enExample)
JP (2) JP6242819B2 (enExample)
KR (3) KR102310704B1 (enExample)
CN (2) CN109535245A (enExample)
AU (3) AU2013219935B2 (enExample)
BR (1) BR122021004014B1 (enExample)
CA (1) CA2870621C (enExample)
CL (2) CL2014002183A1 (enExample)
CO (1) CO7131365A2 (enExample)
DK (2) DK2822576T3 (enExample)
EA (2) EA028578B1 (enExample)
ES (3) ES3010346T3 (enExample)
HU (1) HUE053068T2 (enExample)
IL (2) IL264959B (enExample)
MX (3) MX393997B (enExample)
MY (1) MY172539A (enExample)
NO (1) NO2920022T3 (enExample)
PE (1) PE20142290A1 (enExample)
PL (2) PL3326642T3 (enExample)
PT (1) PT3791890T (enExample)
SG (1) SG11201404836QA (enExample)
WO (1) WO2013121416A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
EP3326642B1 (en) * 2012-02-14 2020-11-25 OPKO Biologics Ltd. Long-acting coagulation factors and uses thereof
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
CN107438623B (zh) * 2014-12-10 2023-07-14 Opko生物科学有限公司 长效的ctp修饰的生长激素多肽的制备方法
HUE055449T2 (hu) * 2015-06-19 2021-11-29 Opko Biologics Ltd Hosszú hatástartamú koagulációs faktorok és eljárások ezek elõállítására
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
TW202444744A (zh) * 2016-07-11 2024-11-16 以色列商歐科生物製品有限公司 長效型凝血因子及其生產方法
EP3502143A4 (en) 2016-08-19 2020-07-15 Ampsource Biopharma Shanghai Inc. BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101595122A (zh) * 2006-02-03 2009-12-02 莫迪格纳公司 长效多肽及其生产和施用方法
US20100317585A1 (en) * 2006-02-03 2010-12-16 Udi Eyal Fima Long-acting coagulation factors and methods of producing same

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
DE3421468A1 (de) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
JP2874751B2 (ja) 1986-04-09 1999-03-24 ジェンザイム・コーポレーション 希望する蛋白質をミルク中へ分泌する遺伝子移植動物
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
ATE148171T1 (de) 1989-02-21 1997-02-15 Univ Washington Modifizierte formen von fortpflanzungshormonen
US5792460A (en) * 1989-02-21 1998-08-11 Washington University Modified glycoprotein hormones having a CTP at the amino terminus
US6225449B1 (en) 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
US7795210B2 (en) * 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
CN1245510C (zh) * 2003-09-25 2006-03-15 复旦大学 长效重组组织因子途径抑制物及其制备方法
US8048849B2 (en) * 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8759292B2 (en) * 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
TWI538916B (zh) * 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
MX2011000847A (es) * 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
EP3326642B1 (en) 2012-02-14 2020-11-25 OPKO Biologics Ltd. Long-acting coagulation factors and uses thereof
EA033788B1 (ru) * 2012-11-20 2019-11-26 Opko Biologics Ltd Способ увеличения гидродинамического объема полипептида путем присоединения карбоксиконцевого пептида гонадотропина

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101595122A (zh) * 2006-02-03 2009-12-02 莫迪格纳公司 长效多肽及其生产和施用方法
US20100317585A1 (en) * 2006-02-03 2010-12-16 Udi Eyal Fima Long-acting coagulation factors and methods of producing same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M.M.MATZUK ET AL.: ""The Biological Role of the Carboxyl-Terminal Extension of Human Chorionic Gonadotroin β-Subunit"", 《ENDOCRINOLOGY》 *
冀倩倩等: ""重组人长效凝血因子Ⅶ药物研发进展"", 《药学进展》 *

Also Published As

Publication number Publication date
JP6510002B2 (ja) 2019-05-08
MX393997B (es) 2025-03-24
PT3791890T (pt) 2025-02-14
ES2665319T3 (es) 2018-04-25
AU2017219044B2 (en) 2019-05-30
DK3326642T3 (da) 2021-02-22
PE20142290A1 (es) 2015-01-15
CL2014002183A1 (es) 2015-01-09
EP2822576A4 (en) 2015-11-25
MX2014009910A (es) 2015-09-28
EP3791890A1 (en) 2021-03-17
KR20140134673A (ko) 2014-11-24
EA028578B1 (ru) 2017-12-29
ES2855133T3 (es) 2021-09-23
AU2016202829A1 (en) 2016-05-19
EP3326642B1 (en) 2020-11-25
SG11201404836QA (en) 2014-12-30
HK1205460A1 (en) 2015-12-18
CA2870621A1 (en) 2013-08-22
EP2822576A1 (en) 2015-01-14
ES3010346T3 (en) 2025-04-02
MX2022008807A (es) 2022-08-11
AU2017219044A1 (en) 2017-09-14
EP2822576B1 (en) 2018-01-10
JP2015508771A (ja) 2015-03-23
MX2019000708A (es) 2020-09-02
IL282121B (en) 2022-06-01
EA201790960A3 (ru) 2018-01-31
EP3791890B1 (en) 2024-11-13
MY172539A (en) 2019-11-30
EP3326642A1 (en) 2018-05-30
BR122021004014B1 (pt) 2022-12-27
PL3791890T3 (pl) 2025-04-14
HUE053068T2 (hu) 2021-06-28
EP4488289A2 (en) 2025-01-08
CN104427994A (zh) 2015-03-18
CA2870621C (en) 2022-08-09
AU2016202829B2 (en) 2017-05-25
AU2013219935A1 (en) 2014-09-25
MX362446B (es) 2019-01-18
KR102118729B1 (ko) 2020-06-05
AU2013219935B2 (en) 2016-02-04
KR20200063274A (ko) 2020-06-04
IL264959B (en) 2021-08-31
JP6242819B2 (ja) 2017-12-06
EP4488289A3 (en) 2025-03-19
EA201790960A2 (ru) 2017-09-29
KR102310704B1 (ko) 2021-10-08
WO2013121416A1 (en) 2013-08-22
CL2017002233A1 (es) 2018-05-11
CO7131365A2 (es) 2014-12-01
EA201491519A1 (ru) 2014-12-30
KR102630953B1 (ko) 2024-01-29
PL3326642T3 (pl) 2021-06-14
JP2018065815A (ja) 2018-04-26
NO2920022T3 (enExample) 2018-06-09
DK2822576T3 (en) 2018-04-16
IL282121A (en) 2021-05-31
BR112014020198A2 (pt) 2018-05-15
KR20210125595A (ko) 2021-10-18

Similar Documents

Publication Publication Date Title
CN109535245A (zh) 长效凝血因子和生产它们的方法
US10144921B2 (en) Long-acting coagulation factors and methods of producing same
US11066658B2 (en) Long-acting coagulation factors and methods of producing same
US8759292B2 (en) Long-acting coagulation factors and methods of producing same
AU2020203459B2 (en) Long-acting coagulation factors and methods of producing same
JP2018008935A (ja) 長期作用性凝固因子およびそれを製造する方法
CN109563145A (zh) 长效凝血因子及其制备方法
US12203113B2 (en) Long-acting coagulation factors and methods of producing same
AU2017201513B2 (en) Long-acting coagulation factors and methods of producing same
EA044349B1 (ru) Факторы свертывания крови пролонгированного действия и способы их получения
BR112014020198B1 (pt) Fator de coagulação modificado por peptídeos carbóxiterminais da gonadotrofina coriônica (ctp) e seu uso, método para produzir e extender a meia-vida do referido fator de coagulação, polinucleotídeo e composição farmacêutica

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination